SFTPD and serous adenocarcinoma: The Hendrix dataset (31) demonstrated that SP-D (SFTPD) is expressed in a wide range of ovarian cancers such as: clear cell adenocarcinoma (n = 8), endometrioid adenocarcinoma (n = 37), mucinous adenocarcinoma (n = 13), serous adenocarcinoma (n = 41) and normal ovaries (n = 4).